Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: Preliminary data

Journal of Rheumatology

Volumn 32, Issue 11, 2005, Pages 2183-2185

  Delaunay, Caroline ^a   Farrenq, Valérie ^a   Marini Portugal, André ^a   Cohen, Jean David ^a   Chevalier, Xavier ^a   Claudepierre, Pascal ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Anti tumor necrosis factor; Etanercept; Infliximab; Psoriatic arthritis; Spondyloarthropathy; Switch treatment

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; ASTHENIA; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INFUSION; FEMALE; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT OUTCOME; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27744533609     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Sanmarti R, Gomez-Puerta JA, Rodriguez-Cros JR, Albaladejo C, Munoz-Gomez J, Canete JD. Etanercept in rheumatoid arthritis patients with a poor therapeutic response in infliximab. Med Clin (Barc) 2004;122:321-4.
2. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
3. Yazici Y, Erkan D. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis 2004;63:607-8.
4. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
5. Brocq O, Plubel Y, Breuil V, et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF-alpha. Presse Med 2002;31:1836-9.
6. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
7. Felson DT, Anderson JI, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
8. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum 1996;39:2013-20.
9. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
10. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
11. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.